Syndrome of inappropriate antidiuretic hormone secretion (SIADH): optimal management
G Mentrasti, L Scortichini, M Torniai… - … and clinical risk …, 2020 - Taylor & Francis
Hyponatremia, defined as serum sodium concentration< 135 mEq/l, is the most common
electrolyte balance disorder in clinical practice. Many causes are listed, but syndrome of …
electrolyte balance disorder in clinical practice. Many causes are listed, but syndrome of …
Hyponatremia and cancer: from bedside to benchside
B Fibbi, G Marroncini, L Naldi, C Anceschi, A Errico… - Cancers, 2023 - mdpi.com
Simple Summary This review article is focused on hyponatremia in cancer patients.
Hyponatremia is the most common electrolyte disorder in these patients and there is …
Hyponatremia is the most common electrolyte disorder in these patients and there is …
Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III …
JH Kim, MH Ryu, YS Park, J Ma, SY Lee, D Kim… - BMC cancer, 2022 - Springer
Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy
improved survival compared to placebo in patients with pretreated advanced gastric cancer …
improved survival compared to placebo in patients with pretreated advanced gastric cancer …
[HTML][HTML] Summary of the International Conference on Onco-Nephrology: an emerging field in medicine
Onco-nephrology is an emerging field in medicine. Patients with cancer may suffer from
kidney diseases because of the cancer itself and cancer-related therapy. It is critical for …
kidney diseases because of the cancer itself and cancer-related therapy. It is critical for …
Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: a comprehensive analysis of 358 patients
LL Huang, XS Hu, Y Wang, JL Li, HY Wang… - Thoracic …, 2021 - Wiley Online Library
Background Extensive‐stage small cell lung cancer (ES‐SCLC) is deemed as a fatal
malignancy with a poor prognosis. Although immunotherapy has gradually played an …
malignancy with a poor prognosis. Although immunotherapy has gradually played an …
[HTML][HTML] Hyponatremia in the cancer patient
Hyponatremia is a common electrolyte disorder observed in a wide variety of malignancies
and is associated with substantial morbidity and mortality. Newer cancer therapies have …
and is associated with substantial morbidity and mortality. Newer cancer therapies have …
Hyponatremia in patients with hematologic diseases
E Koumpis, M Florentin, E Hatzimichael… - Journal of Clinical …, 2020 - mdpi.com
Hyponatremia is the most common electrolyte disorder in clinical practice and is associated
with increased morbidity and mortality. It is frequently encountered in hematologic patients …
with increased morbidity and mortality. It is frequently encountered in hematologic patients …
Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy
The aim of the study was to assess, for the first time, the prognostic role of hyponatremia and
sodium normalization in patients receiving first-line chemo-or targeted therapy for advanced …
sodium normalization in patients receiving first-line chemo-or targeted therapy for advanced …
Managing hyponatremia in lung cancer: latest evidence and clinical implications
I Fiordoliva, T Meletani, MG Baleani… - … in medical oncology, 2017 - journals.sagepub.com
Hyponatremia is the most common electrolyte disorder in lung cancer patients. This
condition may be related to many causes including incidental medications, concurrent …
condition may be related to many causes including incidental medications, concurrent …
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc …
Background The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy
was superior to placebo for patients with pretreated advanced gastric or gastroesophageal …
was superior to placebo for patients with pretreated advanced gastric or gastroesophageal …